fashion -WSS

fashion

author：explore 2025-08-11 09:49:50 - browse：994

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Gene therapy’s promise and the high cost of hope

explore

WSS

Surgery pushed Ben Carson to fame

Life sciences investors close nearly $6 billion in new funds

Updated Covid vaccine has 54% effectiveness, new study suggests

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Coloradans with cystic fibrosis could lose access to Trikafta

explore

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Continuity nursing helped my family in our darkest PICU moments

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Virginia high school admissions case could be legal follow

What’s missing from the debate over nursing home staff minimums

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

Texas Medical Board asked to define abortion emergency exception

Infant mortality in U.S. rose last year for first time in decades: CDC

Gene therapy for Afghan refugees’ infant will be fully covered

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Bill would allow buprenorphine prescription for addiction via telehealth

Devoted Health’s losses in Medicare Advantage persist

knowledge

explore

knowledge

knowledge